Clinical Trial Update: A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study of LVGN6051 in combination with Anlotinib for soft tissue sarcoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Anlotinib (anlotinib)
• LVGN6051

Snippet

Sponsor: Lyvgen Biopharma Holdings Limited | Conditions: Soft Tissue Sarcoma | Phase 1, Phase 2 | Status: RECRUITING